Syneron Medical (Nasdaq: ELOS) reported earnings on May 22. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Syneron Medical met expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue dropped slightly. Non-GAAP earnings per share expanded. GAAP loss per share was unchanged.

Margins grew across the board.

Revenue details
Syneron Medical reported revenue of $61.2 million. The four analysts polled by S&P Capital IQ wanted to see sales of $61.2 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.02. The four earnings estimates compiled by S&P Capital IQ predicted $0.02 per share. Non-GAAP EPS were $0.02 for Q1 compared to -$0.05 per share for the prior-year quarter. GAAP EPS of -$0.07 were the same as the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 53.0%, 160 basis points better than the prior-year quarter. Operating margin was -4.2%, 60 basis points better than the prior-year quarter. Net margin was -4.0%, 20 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
Next quarter's average estimate for revenue is $74.9 million. On the bottom line, the average EPS estimate is $0.12.

Next year's average estimate for revenue is $289.9 million. The average EPS estimate is $0.47.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 700 members out of 732 rating the stock outperform, and 32 members rating it underperform. Among 176 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 171 give Syneron Medical a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Syneron Medical is buy, with an average price target of $16.50.

Is Syneron Medical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.